Navigation Links
Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
Date:5/30/2008

endently develop into valuable assets that directly benefit our shareholders," continued Dr. Mollica.

As the company continues to improve its operational flexibility and strengthen its balance sheet, it has a number of significant opportunities to generate cash including a partnership for PS433540, the continued success of its discovery efforts on behalf of partners, future development milestones and potential royalties for the several clinical candidates discovered by Pharmacopeia that are being advanced by partners such as Schering-Plough and Bristol-Myers Squibb and, when appropriate, accessing the capital markets.

In the second quarter of 2008, Pharmacopeia expects to record a charge of approximately $800,000 in connection with the severance provided to employees directly affected by the reduction in staffing.

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including eight clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Pharmacopeia, Inc.

(609) 452-3643

ir_pr@pcop.com
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
3. Pharmacopeia Announces Management Team Changes
4. Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference
5. Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
6. Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference
7. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
8. Pharmacopeia to Host First Quarter 2008 Financial Results Webcast and Conference Call
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
11. Verenium Advances Its Development Work With Cargill on a New Food-Related Product

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...and, November 24 deCODE,... approval of all of its,"first day" motions by the...e,(the "Bankruptcy Court"). deCODE last week filed...of the United States Bankruptcy Code with the,Bank...Bankruptcy Court allow the company to continue,to ...
(Date:11/24/2009)... Blue Marble Energy Corp. announced today that the...ty (OPDA) were recently awarded $2 million by Wash...oard (CERB) in a private/public partnership to con...refinery in Lincoln County, WA. ,, "This inve... our biorefinery and bring over 70 green jobs to L...
(Date:11/24/2009)...wire-FirstCall/ -- Shire plc (LSE: SHP,NASDAQ: S...pany, today,announced that it has submitted a MAA ... alfa, the company,s enzyme replacement therapy in...isease. This is the third marketing,application fo... previous,submissions in the United States and Can...
(Date:11/24/2009)...ustomers with Partners Validated to Process and An... , Ottawa, ON (PRWEB) Nove... of products for biological sample collection, sta...w global partner program. The program offers signi...unity and is designed to help partners scale and d...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
... Corporation,today announced its V-Link Luer-activ...ing, the first needleless intravenous (IV) connect...ilable for hospitals in the,United States and Cana... on,average 99.9 percent or more of specific commo...use catheter-related bloodstream,infections. Patho...
...scussed during Omnicell,educational, programs Apr...nd April,22 at, The Mid-America Club in Chicago, ..., Omnicell, Inc. (Nasdaq: OMCL ), a leading provi...nd operational efficiency in,healthcare facilities...uccessful implementation of SinglePointe(TM), a to...
...., Ph.D. a,physician-geneticist and leader of the ...the inaugural Inamori Ethics Prize from the Inamor...t Case Western Reserve,University., (Photo: http..., The Inamori Ethics Prize honors outstanding int...ly to an individual who has demonstrated,exemplary...
Other Biology Technology:Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 2Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 4Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell 2Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell 3Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 2Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 3Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 4
(Date:11/24/2009)...Scientists have crystallised a protein that may he.... The protein could be used by probiotic producers... benefit to people. , "Probiotics need to interac...ffect, and if they attach to surfaces in the gut t... exert their activity," says Dr Nathalie Juge from...
(Date:11/24/2009)... BATON ROUGE Antarctica has long held secrets of... until recently, there has been very little inform...neath miles of ice for millions of years. Now, a t...ng LSU have been funded to the tune of $10 millio...SF, to get to the bottom of things literally. The...
(Date:11/23/2009)...Washington, D.C. The community-associated strain ...cteria resistant to most common antibioticsposes a...nd is making its way into hospitals, according to ...ous Diseases . , The new threat is easily picke... places and has increased the overall burden of MR...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2The Maurer Foundation for Breast Health Education Launches Integrated Rebranding Operation 52200 1The Maurer Foundation for Breast Health Education Launches Integrated Rebranding Operation 52200 2Swissmedic Grants Debiopharm Marketing Authorisation for Moapar 28R 29 a New Therapeutic Avenue for the Treatment of Sexual Deviations 4759 1Swissmedic Grants Debiopharm Marketing Authorisation for Moapar 28R 29 a New Therapeutic Avenue for the Treatment of Sexual Deviations 4759 2Swissmedic Grants Debiopharm Marketing Authorisation for Moapar 28R 29 a New Therapeutic Avenue for the Treatment of Sexual Deviations 4759 3JACQUES Initiative Joins Maryland AIDS Administration to Extend HIV Testing to the Faith Based Community 52195 1JACQUES Initiative Joins Maryland AIDS Administration to Extend HIV Testing to the Faith Based Community 52195 2JACQUES Initiative Joins Maryland AIDS Administration to Extend HIV Testing to the Faith Based Community 52195 3JACQUES Initiative Joins Maryland AIDS Administration to Extend HIV Testing to the Faith Based Community 52195 4
...by Stephen Dalton, professor and Georgia Research ...he University of Georgia, has been awarded $9.2 mi... National Institute of General Medical Sciences, p...n,s group, headquartered in the department of bioc...olecular underpinnings of the early steps that ste...
...has waged a successful guerrilla war against the h...eek,s Journal of Biological Chemistry has expose...immune proteins, which may aid in future drug deve...mitted to people via infected mosquitoes. Once ins...hop in liver cells, then move into red blood cells...
...cting vast amounts of diverse genomic data with ev...ze these data in an integrated manner have lagged ...is growing need, researchers at the Broad Institut...IGV), a novel and freely available visualization t...analyze different types of genomic data, and gives...
Other Biology News:UGA researchers win $9.2 million stem cell grant from NIH 2Research exposes new target for malaria drugs 2Broad Institute researchers introduce next generation tool for visualizing genomic data 2
Mouse Anti-Human HLA II DG+DR+DP Monoclonal Antibody, Unconjugated, Clone IQU9 from Diaclone
Duck Anti-Phenytoin-BSA Antibody, Unconjugated from Good Biotech Corp
Anti-Tropomyosin 4 Antibody, Unconjugated from CHEMICON
Mouse Anti-Cytokeratin 8 + 18 + 19 Monoclonal Antibody, Unconjugated, Clone 2A4 from Abcam
Biology Products: